TITLE

CAPITOL HEALTH CALL

AUTHOR(S)
Mitka, Mike
PUB. DATE
December 2009
SOURCE
JAMA: Journal of the American Medical Association;12/9/2009, Vol. 302 Issue 22, p2423
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This section presents an update on issues related to medical care in the U.S. The Government Accountability Office (GAO) reported that the marketing oversight of the Food and Drug Administration (FDA) for drugs remained poor from 1998 to 2008. Democratic Representative Michael Honda of California introduced the Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009. Patients with coal workers' pneumoconiosis are entitled to the Black Lung Benefits Program launched by the Department of Labor.
ACCESSION #
45660463

 

Related Articles

  • BRAND-NAME PRESCRIPTION DRUG PRICING: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases.  // GAO Reports;1/11/2010, preceding p1 

    The article highlights the study of Government Accountability Office (GAO) which examines the growing cost of brand-name prescription drugs with extraordinary price increase in the U.S. It notes that Food and Drug Administration-approved drug products that have patent protection concern the...

  • GAO: Launch of ObamaCare insurance exchanges in doubt. Viebeck, Elise // Hill;6/20/2013, Vol. 20 Issue 75, p11 

    The article focuses on a report from the U.S. Government Accountability Office (GAO) regarding the launch of healthcare law by President Barack Obama which might not be ready for prime time when people signed up for the new insurance exchanges on October 1, 2013.

  • Hamburg Describes Efforts to Develop Medical Countermeasures. Drakulich, Angie // Pharmaceutical Technology;Apr2011, Vol. 35 Issue 4, p26 

    The article reports on the potential contribution of Food and Drug Administration (FDA) to the medical countermeasures for responding to natural and deliberate threats to public health in the U.S. in 2011. It mentions the actions to be carried out by the agency which include its cooperation with...

  • FDA moves to streamline patient info. Dickinson, James G. // Medical Marketing & Media;Dec2012, Vol. 47 Issue 12, p34 

    The article reports on the efforts of the drugs center of the U.S. Food and Drug Administration (FDA) to draft a regulation in order to implement the proposed Patient Medication Information (PMI) sheet in the near future.

  • FDA final guidance on 'Dear Healthcare Provider' letters.  // CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p6 

    The article reports that a guidance document titled "Dear Health Care Provider Letters: Improving Communication of Important Safety Information," has been released by the Food & Drug Administration (FDA). It offers information on the content and format of Dear Healthcare Provider (DHCP) letters...

  • Bill Watch.  // McKnight's Long-Term Care News;Jan2012, Vol. 33 Issue 1, p4 

    The article presents information on various medical bills including a new Senate bill that would provide the U.S. Food and Drug Administration a new recall powers and approval of HR 3094 bill by the House that would grant employers more power against quick union organizing efforts.

  • FDA hands down guidance on mobile apps. Newman, Elizabeth // McKnight's Long-Term Care News;Dec2013, Vol. 34 Issue 12, p30 

    The article focuses on guidance issued by the U.S. Food and Drug Administration on mobile medical applications which are intended for helping patients in self-management of disease, document health condition, and track health information and informs that 100 applications had already been approved.

  • Private Health Insurance Coverage: Expert Views on Approaches to Encourage Voluntary Enrollment. Dicken, John E. // GAO Reports;3/25/2011, p1 

    The article presents a report from the U.S. Government Accountability Office (GAO) about the Patient Protection and Affordable Care Act (PPACA). It highlights on the approaches from experts on encouraging individuals to enroll in health care coverage which include changing enrollment periods,...

  • Biosimilars regulations unlikely to unfold soon. DEARMENT, ALARIC // Drug Store News;2/7/2011, Vol. 33 Issue 2, p28 

    The article reports on the repeal of the Patient Protection and Affordable Care Act by the U.S. Congress. It notes that the effort largely is unlikely to succeed, so at least one portion of the healthcare-reform law will remain in effect. Furthermore, it mentions that the Food and Drug...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics